Strong launch of Sandoz's epoetins in Germany
This article was originally published in Scrip
Executive Summary
Novartis’s generics division,Sandoz, has reported biopharmaceutical sales of $97 million (+23% in local currencies) in the first half, which included the "strong launch" of its epoetin products in Germany (epoetin alfa Hexal, Binocrit and Abseamed (Medice)).